Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
RESEARCH TOOLSreports
Holding BDTX?
Track your performance easily
BDTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.62 - $7.66
Previous Close$3.29
Volume535.56K
Average Volume (3M)1.22M
Market Cap
$179.94M
Enterprise Value$86.93M
Total Cash (Recent Filing)$112.68M
Total Debt (Recent Filing)$19.67M
Price to Earnings (P/E)―
Beta3.71
Next Earnings
Mar 12, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding56,585,063
10 Day Avg. Volume651,094
30 Day Avg. Volume1,221,007
Standard Deviation0.34
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.91
Price to Sales (P/S)58.75
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue28.38
Enterprise Value/Gross Profit76.39
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$14.50Price Target Upside340.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Black Diamond Therapeutics News
PremiumCompany Announcements
Black Diamond Therapeutics Reports Promising Q3 2024 Results
PremiumCompany Announcements
Black Diamond Therapeutics Restructures to Focus on Oncology Lead Program
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentBDTX-1535 has demonstrated potent activity against a wide range of EGFR mutations, positioning it as an effective 1L treatment for non-classical EGFR mutations.
Financial PerformanceBlack Diamond reported financial results showing a net loss per share narrower than expected, primarily due to lower-than-anticipated operating expenses.
Research And DevelopmentThe safety profile of BDTX-1535 aligns with approved drugs, showing no severe side effects, enhancing its potential as a safe treatment option.
Bears Say
Drug EfficacyNegative efficacy data for BDTX-1535 or BDTX-4933 could significantly impact investor confidence in the company's future prospects.
Drug SafetyA poorer than expected safety profile for BDTX-1535 or BDTX-4933 may lead to increased regulatory scrutiny and potential delays in approval.
Financial PerformanceReporting a $20MM net loss reflects ongoing financial challenges that may hinder the company's ability to fund further research and development.
---
Ownership Overview
19.45% Insiders
17.23% Mutual Funds
1.20% Other Institutional Investors
54.77% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BDTX FAQ
What was Black Diamond Therapeutics’s price range in the past 12 months?
Black Diamond Therapeutics lowest stock price was $1.62 and its highest was $7.66 in the past 12 months.
What is Black Diamond Therapeutics’s market cap?
Currently, no data Available
When is Black Diamond Therapeutics’s upcoming earnings report date?
Black Diamond Therapeutics’s upcoming earnings report date is Mar 12, 2025 which is in 122 days.
How were Black Diamond Therapeutics’s earnings last quarter?
Black Diamond Therapeutics released its earnings results on Nov 05, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.373 by $0.093.
Is Black Diamond Therapeutics overvalued?
According to Wall Street analysts Black Diamond Therapeutics’s price is currently Undervalued.
Does Black Diamond Therapeutics pay dividends?
Black Diamond Therapeutics does not currently pay dividends.
What is Black Diamond Therapeutics’s EPS estimate?
Black Diamond Therapeutics’s EPS estimate is -$0.31.
How many shares outstanding does Black Diamond Therapeutics have?
Black Diamond Therapeutics has 56,585,064 shares outstanding.
What happened to Black Diamond Therapeutics’s price movement after its last earnings report?
Black Diamond Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.373. Following the earnings report the stock price went up 8.696%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics?
Among the largest hedge funds holding Black Diamond Therapeutics’s share is Driehaus Capital Management LLC. It holds Black Diamond Therapeutics’s shares valued at 3M.
---
Black Diamond Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (340.73% Upside)
$14.50 (340.73% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
77.83%
12-Months-Change
Fundamentals
Return on Equity
-63.09%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Black Diamond Therapeutics
Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
---
BDTX Stock 12 Month Forecast
Average Price Target
$14.50
▲(340.73% Upside)
Technical Analysis
Best Analysts Covering BDTX
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-12.91%
reiterated a buy rating 5 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -12.91% per trade.
---